- Home
- MCRI vs BEAM Comparison
MCRI vs BEAM Comparison
Compare MCRI & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- BEAM
- Stock Information
- Founded
- MCRI 1972
- BEAM 2017
- Country
- MCRI United States
- BEAM United States
- Employees
- MCRI N/A
- BEAM N/A
- Industry
- MCRI Hotels/Resorts
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCRI Consumer Discretionary
- BEAM Health Care
- Exchange
- MCRI Nasdaq
- BEAM Nasdaq
- Market Cap
- MCRI 1.9B
- BEAM 1.7B
- IPO Year
- MCRI 1993
- BEAM 2020
- Fundamental
- Price
- MCRI $103.70
- BEAM $25.75
- Analyst Decision
- MCRI Hold
- BEAM Strong Buy
- Analyst Count
- MCRI 5
- BEAM 10
- Target Price
- MCRI $96.20
- BEAM $49.78
- AVG Volume (30 Days)
- MCRI 92.3K
- BEAM 2.6M
- Earning Date
- MCRI 10-22-2025
- BEAM 11-04-2025
- Dividend Yield
- MCRI 1.16%
- BEAM N/A
- EPS Growth
- MCRI N/A
- BEAM N/A
- EPS
- MCRI 4.22
- BEAM N/A
- Revenue
- MCRI $534,693,999.00
- BEAM $60,272,000.00
- Revenue This Year
- MCRI $6.87
- BEAM N/A
- Revenue Next Year
- MCRI $4.19
- BEAM $18.95
- P/E Ratio
- MCRI $24.60
- BEAM N/A
- Revenue Growth
- MCRI 4.65
- BEAM N/A
- 52 Week Low
- MCRI $69.99
- BEAM $13.53
- 52 Week High
- MCRI $113.88
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- MCRI 51.64
- BEAM 69.64
- Support Level
- MCRI $103.32
- BEAM $22.50
- Resistance Level
- MCRI $107.00
- BEAM $25.09
- Average True Range (ATR)
- MCRI 2.18
- BEAM 1.47
- MACD
- MCRI 0.07
- BEAM 0.13
- Stochastic Oscillator
- MCRI 51.47
- BEAM 92.34
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.